Literature DB >> 28162010

Genetic risk factors for serious infections in inflammatory bowel diseases.

Saranya Sasidharan1, Vijay Yajnik1, Hamed Khalili1, John Garber1, Ramnik Xavier1, Ashwin N Ananthakrishnan1.   

Abstract

INTRODUCTION: Immunosuppression, the cornerstone of management of Crohn's disease (CD) and ulcerative colitis (UC) (inflammatory bowel diseases; IBD) is associated with an increased risk of serious infections that is inadequately predicted by clinical risk factors. The role of genetics in determining susceptibility to infections is unknown.
METHODS: From a prospective-consented patient registry, we identified IBD patients with serious infections requiring hospitalization. Analysis was performed to identify IBD-related and non-IBD related immune response loci on the Immunochip that were associated with serious infections and a genetic risk score (GRS) representing the cumulative burden of the identified single nucleotide polymorphisms was calculated. Multivariable logistic regression used to identify effect of clinical and genetic factors.
RESULTS: The study included 1333 IBD patients (795 CD, 538 UC) with median disease duration of 13 years. A total of 133 patients (10%) had a serious infection requiring hospitalization. Patients with infections were more likely to have CD and had shorter disease duration. The most common infections were skin and soft-tissue, respiratory and urinary tract infections. Eight IBD risk loci and two other polymorphisms were significantly associations with serious infections. Each one point increase in the infection GRS was associated with a 50% increase in risk of infections (OR = 1.53, 95% CI = 1.37-1.70) (p = 1 × 10-14), confirmed on multivariable analysis. Genetic risk factors improved performance of a model predicting infections over clinical covariates alone (p < 0.001).
CONCLUSIONS: Genetic risk factors may predict susceptibility to infections in patients with IBD.

Entities:  

Keywords:  Crohn’s disease; Genetics; immunosuppression; infections; pneumonia; sepsis

Mesh:

Year:  2017        PMID: 28162010      PMCID: PMC5642969          DOI: 10.1080/00365521.2017.1286381

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  48 in total

Review 1.  The role of IFN-gamma in immune responses to viral infections of the central nervous system.

Authors:  David A Chesler; Carol Shoshkes Reiss
Journal:  Cytokine Growth Factor Rev       Date:  2002-12       Impact factor: 7.638

2.  Analysis of Hospital-Based Emergency Department Visits for Inflammatory Bowel Disease in the USA.

Authors:  Mahesh Gajendran; Chandraprakash Umapathy; Priyadarshini Loganathan; Jana G Hashash; Ioannis E Koutroubakis; David G Binion
Journal:  Dig Dis Sci       Date:  2015-09-30       Impact factor: 3.199

Review 3.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

4.  Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases.

Authors:  Massimiliano Sarra; Ivan Monteleone; Carmine Stolfi; Massimo Claudio Fantini; Pierpaolo Sileri; Giuseppe Sica; Roberto Tersigni; Thomas T Macdonald; Francesco Pallone; Giovanni Monteleone
Journal:  Inflamm Bowel Dis       Date:  2010-08       Impact factor: 5.325

5.  Role of nitric oxide synthase type 2 in acute infection with murine cytomegalovirus.

Authors:  S Noda; K Tanaka; S Sawamura ; M Sasaki; T Matsumoto; K Mikami; Y Aiba; H Hasegawa; N Kawabe; Y Koga
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

Review 6.  Opportunistic infections due to inflammatory bowel disease therapy.

Authors:  Maneesh Dave; Treta Purohit; Raymund Razonable; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

7.  CXCL1 regulates pulmonary host defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs.

Authors:  Shanshan Cai; Sanjay Batra; Sergio A Lira; Jay K Kolls; Samithamby Jeyaseelan
Journal:  J Immunol       Date:  2010-10-11       Impact factor: 5.422

Review 8.  Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease.

Authors:  Hans-Jörg Epple
Journal:  Dig Dis       Date:  2009-11-04       Impact factor: 2.404

Review 9.  IFN-gamma therapy of tuberculosis and related infections.

Authors:  Rajko Reljic
Journal:  J Interferon Cytokine Res       Date:  2007-05       Impact factor: 2.607

10.  Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.

Authors:  Mike van der Have; Bas Oldenburg; Herma H Fidder; Tim D G Belderbos; Peter D Siersema; Martijn G H van Oijen
Journal:  Dig Dis Sci       Date:  2013-08-15       Impact factor: 3.199

View more
  2 in total

1.  Maternal Outcomes and Pregnancy-Related Complications Among Hospitalized Women with Inflammatory Bowel Disease: Report from the National Inpatient Sample.

Authors:  Daniela Guerrero Vinsard; Raffi Karagozian; Dorothy B Wakefield; Sunanda V Kane
Journal:  Dig Dis Sci       Date:  2021-08-18       Impact factor: 3.487

2.  Decreased CD8+CD28+/CD8+CD28- T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease.

Authors:  Shi-Xue Dai; Hong-Xiang Gu; Qian-Yi Lin; Yan-Kun Wu; Xiao-Yan Wang; Shao-Zhuo Huang; Tiao-Si Xing; Min-Hua Chen; Qing-Fang Zhang; Zhong-Wen Zheng; Wei-Hong Sha
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.